$56.82▾ 0.28%
End-of-day close · 2026-09-01
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
More coming: dilution / share-count creep.
✦ The read
CRISPR Therapeutics AG - Common Shares's earnings-quality signal is not available yet.
Key numbers
Recent news
Sentiment · last 30 days3 articles
2 bullish1 neutral0 bearish
Hypertension Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Set for Expansion Through 2036, Fueled by Treatment Innovation and Rising Patient Demand
AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Why CRISPR Therapeutics Stock Rocked the Market Last Month